Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 239


Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage.

Kurdistani SK, Arizti P, Reimer CL, Sugrue MM, Aaronson SA, Lee SW.

Cancer Res. 1998 Oct 1;58(19):4439-44.


Integrative genomics revealed RAI3 is a cell growth-promoting gene and a novel P53 transcriptional target.

Wu Q, Ding W, Mirza A, Van Arsdale T, Wei I, Bishop WR, Basso A, McClanahan T, Luo L, Kirschmeier P, Gustafson E, Hernandez M, Liu S.

J Biol Chem. 2005 Apr 1;280(13):12935-43. Epub 2005 Jan 18.


Function of Drg1/Rit42 in p53-dependent mitotic spindle checkpoint.

Kim KT, Ongusaha PP, Hong YK, Kurdistani SK, Nakamura M, Lu KP, Lee SW.

J Biol Chem. 2004 Sep 10;279(37):38597-602. Epub 2004 Jul 9.


Altered regulation of cyclin G in human breast cancer and its specific localization at replication foci in response to DNA damage in p53+/+ cells.

Reimer CL, Borras AM, Kurdistani SK, Garreau JR, Chung M, Aaronson SA, Lee SW.

J Biol Chem. 1999 Apr 16;274(16):11022-9.


Retinoic acid-mediated G1-S-phase arrest of normal human mammary epithelial cells is independent of the level of p53 protein expression.

Seewaldt VL, Dietze EC, Johnson BS, Collins SJ, Parker MB.

Cell Growth Differ. 1999 Jan;10(1):49-59.


Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression.

Li PX, Wong J, Ayed A, Ngo D, Brade AM, Arrowsmith C, Austin RC, Klamut HJ.

J Biol Chem. 2000 Jun 30;275(26):20127-35.


Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer.

Salnikow K, Costa M, Figg WD, Blagosklonny MV.

Cancer Res. 2000 Oct 15;60(20):5630-4.


Human wig-1, a p53 target gene that encodes a growth inhibitory zinc finger protein.

Hellborg F, Qian W, Mendez-Vidal C, Asker C, Kost-Alimova M, Wilhelm M, Imreh S, Wiman KG.

Oncogene. 2001 Sep 6;20(39):5466-74.


DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells.

Zhou M, Gu L, Li F, Zhu Y, Woods WG, Findley HW.

J Pharmacol Exp Ther. 2002 Oct;303(1):124-31.


Tumor cell-specific loss of p53 protein in a unique in vitro model of human breast tumor progression.

Liu XL, Band H, Gao Q, Wazer DE, Chu Q, Band V.

Carcinogenesis. 1994 Sep;15(9):1969-73.


Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells.

Katayose D, Gudas J, Nguyen H, Srivastava S, Cowan KH, Seth P.

Clin Cancer Res. 1995 Aug;1(8):889-97.


PA26, a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes.

Velasco-Miguel S, Buckbinder L, Jean P, Gelbert L, Talbott R, Laidlaw J, Seizinger B, Kley N.

Oncogene. 1999 Jan 7;18(1):127-37.


WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells.

Cuddihy AR, Jalali F, Coackley C, Bristow RG.

Mol Cancer Ther. 2008 Apr;7(4):980-92. doi: 10.1158/1535-7163.MCT-07-0471.


Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression.

Fan R, Kumaravel TS, Jalali F, Marrano P, Squire JA, Bristow RG.

Cancer Res. 2004 Dec 1;64(23):8526-33.


Supplemental Content

Support Center